Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes.

Nascimbeni F, Pellegrini E, Lugari S, Mondelli A, Bursi S, Onfiani G, Carubbi F, Lonardo A.

Atherosclerosis. 2019 May;284:66-74. doi: 10.1016/j.atherosclerosis.2019.02.028. Epub 2019 Mar 3. Review.

PMID:
30875495
2.

Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease.

Nascimbeni F, Cassinerio E, Dalla Salda A, Motta I, Bursi S, Donatiello S, Spina V, Cappellini MD, Carubbi F.

Mol Genet Metab. 2018 Sep;125(1-2):64-72. doi: 10.1016/j.ymgme.2018.08.004. Epub 2018 Aug 11.

PMID:
30115580
3.

Metabolic Syndrome, Anxiety and Depression in a Sample of Italian Primary Care Patients.

Mattei G, Padula MS, Rioli G, Arginelli L, Bursi R, Bursi S, Epifani AM, Pingani L, Rigatelli M, Rosato FM, Sacchetti A, Galeazzi GM, Ferrari S.

J Nerv Ment Dis. 2018 May;206(5):316-324. doi: 10.1097/NMD.0000000000000807.

PMID:
29658910
4.

Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months.

Marconcini R, Galli L, Antonuzzo A, Bursi S, Roncella C, Fontanini G, Sensi E, Falcone A.

Exp Hematol Oncol. 2017 Mar 21;6:6. doi: 10.1186/s40164-017-0067-4. eCollection 2017.

5.

Consequences of targeted treatments for second-line therapy.

De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, Cupini S, Di Marsico R, D'Arcangelo M, Landi L, Minuti G, Cappuzzo F.

Ann Oncol. 2010 Oct;21 Suppl 7:vii234-40. doi: 10.1093/annonc/mdq280. Review.

PMID:
20943621
6.

Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer.

Fontana A, Bocci G, Galli L, D'Arcangelo M, Derosa L, Fioravanti A, Orlandi P, Barletta MT, Landi L, Bursi S, Minuti G, Bona E, Grazzini I, Danesi R, Falcone A.

J Am Geriatr Soc. 2010 May;58(5):986-8. doi: 10.1111/j.1532-5415.2010.02833.x. No abstract available.

PMID:
20722827
7.

Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.

Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G.

Clin Cancer Res. 2009 Aug 1;15(15):4954-62. doi: 10.1158/1078-0432.CCR-08-3317. Epub 2009 Jul 21.

8.

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.

Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, Petrini I, Di Donato S, Brunetti IM, Ricci S, Antonuzzo A, Chiara S, Amoroso D, Andreuccetti M, Falcone A.

Br J Cancer. 2009 Jun 2;100(11):1720-4. doi: 10.1038/sj.bjc.6605075. Epub 2009 May 12.

9.

A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.

Fornaro L, Masi G, Bursi S, Loupakis F, Vasile E, Antonuzzo A, Chiara S, Pfanner E, Di Paolo A, Bocci G, Del Tacca M, Falcone A.

Cancer Chemother Pharmacol. 2009 Apr;63(5):965-9. doi: 10.1007/s00280-008-0840-5. Epub 2008 Oct 7.

PMID:
18839174
10.

Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk.

Roncucci L, Mora E, Mariani F, Bursi S, Pezzi A, Rossi G, Pedroni M, Luppi D, Santoro L, Monni S, Manenti A, Bertani A, Merighi A, Benatti P, Di Gregorio C, de Leon PM.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2291-7. doi: 10.1158/1055-9965.EPI-08-0224.

11.

Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.

Masi G, Vasile E, Loupakis F, Bursi S, Ricci S, Petrini I, Fontana A, Allegrini G, Falcone A.

Clin Colorectal Cancer. 2008 Jan;7(1):7-14. doi: 10.3816/CCC.2008.n.002. Review.

PMID:
18279572
12.

First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.

Masi G, Marcucci L, Loupakis F, Cerri E, Barbara C, Bursi S, Allegrini G, Brunetti IM, Murr R, Ricci S, Cupini S, Andreuccetti M, Falcone A.

Ann Oncol. 2006 Aug;17(8):1249-54. Epub 2006 Jun 9.

PMID:
16766580

Supplemental Content

Support Center